Chronic Kidney Disease Market Size is Projected to Grow at 5.40% CAGR by 2030

Pune, India, August, 2018 /press release/- Market Research Future Published a Half-Cooked Research Report on Global Chronic Kidney Disease Market Research Report.

Market Insights

Market Research Future (MRFR) has released a report on the global chronic kidney disease which projects a moderate CAGR of 5.40% during the assessment period of 2022 to 2030. Rising occurrences of chronic diseases and the severity of kidney disease has increased the demand for an effective treatment option for the disease. Causes of chronic diseases are often indicated by diabetes, polycystic kidney disease, and high blood pressure among others.

Increasing prevalence of kidney diseases and the increased number of biopsy procedures have resulted in high demand for new diagnostic and treatment options for such chronic diseases. The global chronic kidney disease market has become highly competitive with the increasing entry of new market players; this is expected to stimulate growth during the forecast period. Kidney disease symptoms are often negligible in the initial phases, and this type of disease is widely referred to as a "silent disease" as detection often happens when the diseases are progressed to a later stage. This has increased the need for appropriate diagnostic measures and is driving market growth.

Increasing R&D activities with regards to diagnostics and treatment are expected to offer market growth opportunities in the future. Moreover, developing economies offer a wider scope for growth during the forecast period and are expected to affect the market positively.

Market Segmentation

MRFR's report segments the global chronic kidney disease market on the basis of diagnosis, treatment, indication, and end-user. By diagnosis, the market is segmented into blood test, urine test, imaging test, and kidney biopsy. By treatment, the market is segmented into drugs, dialysis, and kidney transplant. Drugs are further sub-segmented to include ace inhibitors, angiotensin-ii receptor blockers, calcium channel blockers, beta-blockers, and erythropoiesis-stimulating agents.

By indication, the market is segmented into Type 1 or Type 2 diabetes, high blood pressure, polycystic kidney disease, and others. By end-user, The market is segmented into hospitals and clinics, diagnostic centers, and others. Globally, the market is divided into the Americas, Europe, Asia-Pacific & the Middle East and Africa.

Regional Analysis

The Americas and Europe are significant regional markets which have a similar growth pattern. The growth of medical devices, increasing awareness regarding kidney diseases and the rapid increase in occurrences of chronic diseases is expected to drive growth in these regions. Moreover, they display a robust demand for new treatment methods and options. Opportunities for these markets are being driven by the increasing emphasis on the development of new drugs. Supportive government legislature with regards to research & development and the availability of funds for research in these regions is expected to push the market in a forward direction.

Asia-Pacific is another important market due to its rapid growth. Prevalence of diseases such as diabetes and cardiovascular diseases are driving the demand for appropriate treatment options. The region has a rapidly improving healthcare sector which has improved infrastructure, and a wide pool of skilled healthcare professionals. Demand for advanced treatment technologies and other healthcare technology is expected to provide the market with opportunities for market expansion.

Key Players

MRFRs report includes the analysis of market players participating in the global chronic kidney diseases competitive landscape. Top market players include Hoffman-La Roche Ltd., Abbott, AstraZeneca Plc, Pfizer, Nova Biomedical, ARKRAY, OPTI Medical, and AbbVie to name a few.

Latest Industry News

Researchers of the Loyola Medicine and Loyola University, Chicago Stritch School of Medicine, have found that medical nutrition therapy is the most important effective way to slow the progression of kidney diseases and prevent failure of the organs.

Johnson & Johnson has recorded highly positive data from the phase III of its chronic kidney diseases study of the drug Invokana. The company plans to release details regarding findings at a scientific conference soon.